This clinical tumor sample was obtained from a patient with BRAF V600-mutated melanoma who was treated with BRAF and MEK inhibitors and developed a metastatic lesion with acquired resistance coincident with the acquisition of ecDNA (Fig. 2a). This evidence concerns the gene MAP2K7 and neoplasm.